Search

Your search keyword '"Bulusu, Ramesh"' showing total 19 results
Start Over Author "Bulusu, Ramesh"
19 results on '"Bulusu, Ramesh"'

1. Performance Comparison of Julia with C and Python for Solving Computational Problems

Author

Krishna, Sabbi Vamshi, Jadhav, Om, Ardhapurkar, Parikshit, Valmiki, Manjunatha, Agrawal, Sandeep, Bulusu, Ramesh, Dinde, Prashant, Wandhekar, Sanjay, Ghosh, Ashish, Editorial Board Member, Zhou, Lizhu, Editorial Board Member, Singh, Mayank, editor, Tyagi, Vipin, editor, Gupta, P. K., editor, Flusser, Jan, editor, Ören, Tuncer, editor, Cherif, Amar Ramdane, editor, and Tomar, Ravi, editor

Published
2025
Full Text
View/download PDF

3. 4 Clinical and molecular characteristics of BRAF mutant Lung Adenocarcinomas

Author

Bulusu, Ramesh, primary, Bulusu, Ramesh, additional, Yang, Huiqi, additional, Patterson, Daniel, additional, Thippu Jayaprakash, Kamalram, additional, McGeogh, Adam, additional, Hutka, Margaret, additional, Hollingdale, Abigail, additional, Treece, Sarah, additional, Thompson, Nicola, additional, Earwaker, Philip, additional, Lynskey, Diedre, additional, Aslam, Shahzeena, additional, and Shiarli, Anna Marie, additional

Published
2024
Full Text
View/download PDF

5. Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: results from the VISION study and local UK experience

Author

Cui, Wanyuan, primary, Brown, Nick, additional, Brown, Victoria, additional, Bulusu, Ramesh, additional, Denton, Arshi, additional, Evans, Joanne, additional, Forster, Martin, additional, Papadatos-Pastos, Dionysis, additional, Pellegrino, Loredana, additional, Walsh, Nessa, additional, Bruns, Rolf, additional, Otto, Gordon, additional, and Paik, Paul, additional

Published
2022
Full Text
View/download PDF

9. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications

Author

Szucs, Z., Thway, K., Fisher, Cyril, Bulusu, Ramesh, Constantinidou, Anastasia, Benson, Charlotte, Graaf, W. T. A. van der, Jones, Robin Lewis, and Constantinidou, Anastasia [0000-0001-5316-7574]

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Stromal cell, Genotype, Gastrointestinal Stromal Tumors, Pfgfra, Clinical Decision-Making, PDGFRA, 03 medical and health sciences, 0302 clinical medicine, Clinical decision making, Internal medicine, Gene Duplication, Gene duplication, medicine, Biomarkers, Tumor, Animals, Humans, Sdh deficiency, neoplasms, Sequence Deletion, Gist, Heterogeneous group, GiST, business.industry, 'wild-type' gist, Imatinib, Kit, General Medicine, Molecular subgroups, Prognosis, digestive system diseases, Braf, Proto-Oncogene Proteins c-kit, 030104 developmental biology, Nf-1, 030220 oncology & carcinogenesis, Immunology, business, medicine.drug, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
Abstract

Contains fulltext : 177634.pdf (Publisher’s version ) (Open Access) Gastrointestinal stromal tumors (GISTs) are composed of various molecular subtypes, with differing prognostic and predictive relevance. Previously, tumors lacking mutations in the KIT and PDGFRA genes have been designated as 'wild-type' GISTs; however, they represent a heterogeneous group currently undergoing further subclassification. Primary and secondary resistance to imatinib poses a significant clinical challenge, therefore ongoing research is trying to evaluate mechanisms to overcome resistance. Thorough understanding of the prognostic and predictive relevance of different genetic subtypes of GIST can guide clinical decision-making both in the adjuvant and the metastatic setting. Further work is required to identify tailored therapies for specific subgroups of GISTs wild-type for KIT and PDGFRA mutations and to identify predictive factors of resistance to currently approved systemic therapies.

Published
2017

10. Promising novel therapeutic approaches in the management of gastrointestinal stromal tumors

Author

Szucs, Z., Thway, K., Fisher, Cyril, Bulusu, Ramesh, Constantinidou, Anastasia, Benson, Charlotte, Graaf, W. T. A. van der, Jones, Robin Lewis, and Constantinidou, Anastasia [0000-0001-5316-7574]

Subjects
0301 basic medicine, Cancer Research, Receptor, Platelet-Derived Growth Factor alpha, Stromal cell, Gastrointestinal Stromal Tumors, Pfgfra, Antineoplastic Agents, PDGFRA, Disease, Immunomodulation, 03 medical and health sciences, 0302 clinical medicine, Novel therapy, Humans, Medicine, Molecular Targeted Therapy, Stromal tumor, Protein Kinase Inhibitors, Gist, GiST, business.industry, Disease Management, Kit, General Medicine, Immune checkpoint, DNA-Binding Proteins, Clinical trial, Proto-Oncogene Proteins c-kit, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Mutation, Immunology, Cancer research, business, Tyrosine kinase, Signal Transduction, Transcription Factors, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
Abstract

Contains fulltext : 177453.pdf (Publisher’s version ) (Open Access) Primary and secondary resistance to currently available licensed tyrosine kinase inhibitors poses a real clinical challenge in the management of advanced gastrointestinal stromal tumors. Within the frame of early phase clinical trials novel systemic treatments are currently being evaluated to target both the well explored and novel emerging downstream effectors of KIT and PDGFRA signaling. Alternative therapeutic approaches also include exploring novel inhibitors of the KIT/PDGFRA receptors, immune checkpoint and cyclin-dependent kinase inhibitors. The final clinical trial outcome data for these agents are highly anticipated. Integration of new diagnostic techniques into routine clinical practice can potentially guide tailored delivery of agents in the treatment of a highly polyclonal, heterogeneous disease such as heavily pretreated advanced gastrointestinal stromal tumor.

Published
2017

12. The role of in vivo metabolomics using H-MRS in SDH deficient disease

Author

Casey, Ruth, primary, McLean, Mary, additional, Bassetti, Madhu, additional, Challis, Ben, additional, Simpson, Helen, additional, Gurnell, Mark, additional, Bulusu, Ramesh, additional, Marker, Alison, additional, Giger, Olivier, additional, Allinson, Kieran, additional, Chatterjee, Krishna, additional, Maher, Eamonn, additional, and Gallagher, Ferdia, additional

Published
2017
Full Text
View/download PDF

14. Interim PET Scan Does Not Predict Outcome in Primary Mediastinal B Cell Lymphoma Treated with R DA EPOCH

Author

Prahladan, Mahesh, primary, Grigoropoulos, Nicholas F, additional, Munisamy, Sreetharan, additional, Hodson, Andrew, additional, Shaw, Ashley, additional, Wright, Penny, additional, Wlliam, Michael, additional, Bulusu, Ramesh, additional, Sureda, Anna, additional, Crawley, Charles, additional, Cheow, Hk, additional, and Follows, George, additional

Published
2012
Full Text
View/download PDF

18. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications.

Author

Szucs Z, Thway K, Fisher C, Bulusu R, Constantinidou A, Benson C, van der Graaf WT, and Jones RL

Subjects
Animals, Clinical Decision-Making, Gastrointestinal Stromal Tumors mortality, Gastrointestinal Stromal Tumors therapy, Gene Duplication, Genotype, Humans, Prognosis, Proto-Oncogene Proteins c-kit genetics, Proto-Oncogene Proteins c-kit metabolism, Sequence Deletion, Biomarkers, Tumor, Gastrointestinal Stromal Tumors diagnosis, Gastrointestinal Stromal Tumors genetics
Abstract

Gastrointestinal stromal tumors (GISTs) are composed of various molecular subtypes, with differing prognostic and predictive relevance. Previously, tumors lacking mutations in the KIT and PDGFRA genes have been designated as 'wild-type' GISTs; however, they represent a heterogeneous group currently undergoing further subclassification. Primary and secondary resistance to imatinib poses a significant clinical challenge, therefore ongoing research is trying to evaluate mechanisms to overcome resistance. Thorough understanding of the prognostic and predictive relevance of different genetic subtypes of GIST can guide clinical decision-making both in the adjuvant and the metastatic setting. Further work is required to identify tailored therapies for specific subgroups of GISTs wild-type for KIT and PDGFRA mutations and to identify predictive factors of resistance to currently approved systemic therapies.

Published
2017
Full Text
View/download PDF

19. Promising novel therapeutic approaches in the management of gastrointestinal stromal tumors.

Author

Szucs Z, Thway K, Fisher C, Bulusu R, Constantinidou A, Benson C, van der Graaf WT, and Jones RL

Subjects
Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, DNA-Binding Proteins antagonists & inhibitors, Disease Management, Gastrointestinal Stromal Tumors diagnosis, Gastrointestinal Stromal Tumors genetics, Gastrointestinal Stromal Tumors metabolism, Humans, Immunomodulation drug effects, Mutation, Protein Kinase Inhibitors pharmacology, Protein Kinase Inhibitors therapeutic use, Proto-Oncogene Proteins c-kit antagonists & inhibitors, Receptor, Platelet-Derived Growth Factor alpha antagonists & inhibitors, Signal Transduction drug effects, Transcription Factors antagonists & inhibitors, Gastrointestinal Stromal Tumors therapy, Molecular Targeted Therapy
Abstract

Primary and secondary resistance to currently available licensed tyrosine kinase inhibitors poses a real clinical challenge in the management of advanced gastrointestinal stromal tumors. Within the frame of early phase clinical trials novel systemic treatments are currently being evaluated to target both the well explored and novel emerging downstream effectors of KIT and PDGFRA signaling. Alternative therapeutic approaches also include exploring novel inhibitors of the KIT/PDGFRA receptors, immune checkpoint and cyclin-dependent kinase inhibitors. The final clinical trial outcome data for these agents are highly anticipated. Integration of new diagnostic techniques into routine clinical practice can potentially guide tailored delivery of agents in the treatment of a highly polyclonal, heterogeneous disease such as heavily pretreated advanced gastrointestinal stromal tumor.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results